Stockreport

Kymera gets FDA clearance for Phase 1 testing of KT-621 [Seeking Alpha]

Kymera Therapeutics, Inc.  (KYMR) 
PDF The biotech company plans to begin a Phase 1 study in October, with data expected in the first half of 2025. More on Kymera Therapeutics Kymera's Protein Degradatio [Read more]